2026-04-17T00:49:56Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/345262025-12-05T09:21:48Zcom_2072_1057col_2072_478799col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Kurdián, Melania author Herrero Fresneda, Immaculada author Lloberas Blanch, Núria author Giménez Bonafé, Pepita author Coria, Virginia author Grande, María T. author Boggia, José author Malacrida, Leonel author Torras Ambròs, Joan author Arévalo, Miguel A. author González-Martínez, Francisco author López-Novoa, José M. author Grinyó Boira, Josep M. author Noboa, Oscar author 2013-04-11T11:31:24Z 2013-04-11T11:31:24Z 2012-03-12 2013-04-11T11:31:24Z The immunosuppressive mammalian target of rapamycin (mTOR) inhibitors are widely used in solid organ transplantation, but their effect on kidney disease progression is controversial. mTOR has emerged as one of the main pathways regulating cell growth, proliferation, differentiation, migration, and survival. The aim of this study was to analyze the effects of delayed inhibition of mTOR pathway with low dose of everolimus on progression of renal disease and TGFβ expression in the 5/6 nephrectomy model in Wistar rats. Medicaments Transplantament renal Proteïnúria Immunosupressió Drugs Kidney transplantation Proteinuria Immunosuppression Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model